Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 14/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138189 | 0.84 | HTT (0.40) | BDKRB1 | |
| SCHEMBL4155517 | 0.84 | ALKBH5 (0.34) | NPY5RBDKRB1PDCD1CD274HTR1A | |
| SCHEMBL5951049 | 0.81 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL4154594 | 0.81 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL4142908 | 0.81 | NPY5R (0.47) | NPY5RBDKRB1HTR1A | |
| SCHEMBL3570796 | 0.78 | MAP3K14 (0.41) | BDKRB1PDCD1CD274 | |
| SCHEMBL3570792 | 0.78 | MAP3K14 (0.41) | BDKRB1PDCD1CD274 | |
| SCHEMBL4134116 | 0.77 | BDKRB1 (0.43) | BDKRB1PDCD1CD274HTR1A | |
| SCHEMBL4149466 | 0.77 | BDKRB1 (0.37) | NPY5RBDKRB1PDCD1CD274HTR1A | |
| SCHEMBL4150130 | 0.77 | DPP7 (0.38) | NPY5RBDKRB1HTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | NPY5R 1154/4885BDKRB1 51/4885PDCD1 4418/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | NPY5R 1154/4885BDKRB1 51/4885PDCD1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.